A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Inclusion Criteria

• •Male or female
• •Age above or equal to 18 years at the time of signing informed consent
• •1. Body Mass Index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or
• •2. BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to, type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
• •For participants with Type 2 diabetes (T2D) at screening the following criteria also apply:
• •Diagnosed with type 2 diabetes mellitus greater than equal to 180 days before screening
• •Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i)), thiazolidinediones, or sulphonylureas (SUs) as a single agent or in combination) according to local label
• •Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 60 days before screening
• •Glycated Haemoglobin (HbA1c) 7 percent-10 percent (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as measured by the central laboratory at screening